Received Apr 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | UNK | — | OT |
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | UNK | y015100 | OT |
No side effects or symptoms reported. No Additional AE; HCP called to report a patient received MMR II (03/01/2025) and then received VARIVAX 7 days later (03/07/2025) instead of the recommended 4-week interval. No side effects or symptoms reported. No Additional information provided. No Additional AE/ N; This spontaneous report was received from a pharmacist and refers to a patient of unknown age and gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 01-MAR-2025, the patient was vaccinated with measles, mumps, and rubella (Wistar RA 27-3) virus vaccine, live (M-M-R II) injection (exact dose, dose number, route of administration, anatomical location, lot # and expiration date were not reported) and on 07-MAR-2025, with varicella virus vaccine live (Oka-Merck) (VARIVAX) injection, 0.5 ml, lot# Y015100, expiration date: 06-SEP-2026 (dose number, route of administration and anatomical location were not provided), both reconstituted with sterile diluent (MERCK STERILE DILUENT) (dose, route of administration, lot# and expiration date were not provided), for prophylaxis. The vaccines were administered in 7-day interval instead of recommended 4-week interval (Inappropriate schedule of product administration). No side effects, symptoms or additional adverse event were reported. Lot# is being requested and will be submitted if received.
Sterile diluent